Continuous Dosing Improves Progression-free Survival for Melanoma Patients with Common Mutations

A first-of-its-kind randomized clinical trial offers strong and perhaps surprising evidence that a combination of two targeted melanoma drugs when given continuously keeps patients' cancer from growing or spreading longer when compared with intermittent treatment, according to study results to be presented at the 2020 virtual annual meeting of the American Association for Cancer Research.
from Medical Xpress - latest medical and health news stories https://ift.tt/3aA10Dm